Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S de Bono

Showing results (411-420 of 426) with videos related to

Pageof 43
Sort By:
Molecular Cancer Therapeutics|February 27, 2024
Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate CancerAntje Neeb, Ines Figueiredo, Denisa Bogdan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2016
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3Howard I Scher, Michael J Morris, Walter M Stadler, et al.
Nature Genetics|June 2, 2019
Publisher Correction: The long tail of oncogenic drivers in prostate cancerJoshua Armenia, Stephanie A M Wankowicz, David Liu, et al.
Nature Genetics|April 4, 2018
The long tail of oncogenic drivers in prostate cancerJoshua Armenia, Stephanie A M Wankowicz, David Liu, et al.
Nature|October 16, 2023
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistanceChristina Guo, Adam Sharp, Bora Gurel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2018
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocolM R Sydes, M R Spears, M D Mason, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 5, 2015
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015S Gillessen, A Omlin, G Attard, et al.
Lancet (London, England)|December 26, 2021
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocolGerhardt Attard, Laura Murphy, Noel W Clarke, et al.
The New England Journal of Medicine|June 6, 2017
Abiraterone for Prostate Cancer Not Previously Treated with Hormone TherapyNicholas D James, Johann S de Bono, Melissa R Spears, et al.
The New England Journal of Medicine|October 29, 2015
DNA-Repair Defects and Olaparib in Metastatic Prostate CancerJoaquin Mateo, Suzanne Carreira, Shahneen Sandhu, et al.
Pageof 43

Showing results (411-420 of 426) with videos related to

Sort By:
Pageof 43
Molecular Cancer Therapeutics|February 27, 2024
Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate CancerAntje Neeb, Ines Figueiredo, Denisa Bogdan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2016
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3Howard I Scher, Michael J Morris, Walter M Stadler, et al.
Nature Genetics|June 2, 2019
Publisher Correction: The long tail of oncogenic drivers in prostate cancerJoshua Armenia, Stephanie A M Wankowicz, David Liu, et al.
Nature Genetics|April 4, 2018
The long tail of oncogenic drivers in prostate cancerJoshua Armenia, Stephanie A M Wankowicz, David Liu, et al.
Nature|October 16, 2023
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistanceChristina Guo, Adam Sharp, Bora Gurel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 13, 2018
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocolM R Sydes, M R Spears, M D Mason, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 5, 2015
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015S Gillessen, A Omlin, G Attard, et al.
Lancet (London, England)|December 26, 2021
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocolGerhardt Attard, Laura Murphy, Noel W Clarke, et al.
The New England Journal of Medicine|June 6, 2017
Abiraterone for Prostate Cancer Not Previously Treated with Hormone TherapyNicholas D James, Johann S de Bono, Melissa R Spears, et al.
The New England Journal of Medicine|October 29, 2015
DNA-Repair Defects and Olaparib in Metastatic Prostate CancerJoaquin Mateo, Suzanne Carreira, Shahneen Sandhu, et al.
Pageof 43